Sun Pharmaceutical Industries is paying $14.00 a share to buy Organon. The stock trades at $13.90. Those two numbers, sitting ten cents apart, should end the conversation. They don’t, because the gap between what Organon earns and what its price implies is wider than a single acquisition spread suggests.
Organon was born in June 2021 when Merck spun it off, handing it a portfolio of women’s health products, biosimilars, and older branded drugs, along with nearly ten billion dollars in debt on day one. The idea was that a focused company could wring more value from these assets than a pharma giant could. For a while, the math held. Then Nexplanon, the contraceptive implant that was supposed to be the growth engine, ran into policy headwinds and a CEO departure tied to improper sales practices. The endometriosis drug in Phase 3 failed its trial in October 2026. By April 2026, management had agreed to sell the whole business to Sun Pharma for an enterprise value of $11.75 billion. The story, it seemed, was over.
Except the filings tell a more complicated version.
The story, briefly
Organon’s filed net margin collapsed from double digits in 2023 to low single digits in 2025, a trough driven by one-time charges rather than a structural collapse in the underlying business. The adjusted EBITDA margin, which strips those charges out, held near 31% through the third quarter of 2026. The stock at $13.90 sits a dime below the agreed acquisition price of $14.00, so the market is pricing in deal completion, not a fundamental rerating. The open question is whether the deal closes on schedule, and what the filings say about the business Sun Pharma is actually buying.
What the margin history actually shows
The headline number that stops people cold is the FY2025 net margin, down sharply from FY2023. That looks like a business falling apart. But net margin is sensitive to one-time items. The adjusted EBITDA margin for full-year 2025 was just over 30%, and the Q3 2026 filing shows it edged slightly lower for the quarter, at 31.9% versus 32.3% in Q3 2025. EBITDA strips out interest, taxes, and non-cash charges, so it measures the cash the core business generates before the debt bill arrives. Think of it as the operating engine, separate from the financing structure sitting on top of it.
The engine is running. The financing structure is the problem. Organon carried long-term debt as of late 2026 that was more than twice the company’s entire market value. A household that owed twice its annual income in credit-card debt and paid a third of its take-home on interest would look financially distressed on paper even if the job was stable. That is roughly Organon’s situation. The GAAP earnings per share were a fraction of the non-GAAP adjusted figure, because the gap between those two numbers is mostly interest expense and acquisition-related charges.
For a saver trying to read this business, the margin story is: the operating business is generating cash at roughly 30 cents on every revenue dollar, but most of that cash is spoken for by debt service before it reaches equity holders.
The price Sun Pharma is paying, and what it implies
The enterprise value Sun Pharma agreed to in April 2026 works out to a modest multiple of the adjusted EBITDA Organon guided for full-year 2026. The market’s own valuation gauge sits at a small premium to that deal multiple, which is consistent with a narrow arbitrage spread rather than any independent valuation thesis. In plain terms: the market is not making a bet on Organon’s future earnings. It is making a bet on whether the deal closes.
Stockholders approved the acquisition in July 2026. Organon has suspended earnings calls and withdrawn forward guidance. The quarterly dividend was cut to a token amount, a yield of under 1% at current prices, a signal that management is not trying to reward holders who stay, only to keep the lights on until closing.
The tension the price creates is narrow but real. The consensus analyst valuation estimate, per MarketBeat data from November 2026, averages well below the current share price, with the high end at the deal price itself. The handful of analysts still covering the stock lean toward “Reduce” or “Hold.” Anyone buying today is not buying a valuation discount. They are buying deal-close probability.
What the filings say about the business Sun Pharma inherits
Revenue has been remarkably flat for five years. The FY2023 10-K and the FY2025 10-K show totals that are nearly identical. That is not growth, but it is also not collapse. The biosimilars segment is the one moving part with genuine upside: Hadlima, the adalimumab biosimilar, has been growing, and Organon secured what it called a first-mover position for its pertuzumab biosimilar, Poherdy, in the US and Europe. Against that, Women’s Health revenue fell sharply in early 2026, driven by a steep drop in US Nexplanon sales tied to policy headwinds. The endometriosis pipeline candidate failed in October 2026. The FDA did extend Nexplanon’s approved duration to five years in January 2026, which helps the product’s competitive position even as near-term volumes are under pressure.
The adjusted gross margin in Q3 2026 was just under 60%, down a fraction from a year earlier. That is a small move, but the direction matters: pricing pressure, product mix shifting toward lower-margin biosimilars, and currency drag are all working against the margin, not for it. Sun Pharma is acquiring a business with a stable revenue base, a durable cash margin around 30%, and a debt load that will require either refinancing or paydown to unlock equity value.
The Jada divestiture in January 2026 raised several hundred million dollars and went toward debt reduction, a sign that the deleveraging path exists, even if it is slow. At the current pace, paying down a meaningful portion of the debt would consume years of free cash flow, assuming no other demands on that cash.
Reading the numbers
- $6.2 billion, FY2025 revenue (10-K filed 2026). What it is: total sales across all three segments for the year. What it means here: revenue has barely moved in five years, which tells you this is a mature business, not a growth story. Everyday version: a shop that took in $6,200 in 2021 took in $6,200 in 2025. The owner is not expanding; they are managing.
- 30.7% adjusted EBITDA margin, FY2025. What it is: for every dollar of revenue, about 31 cents survived after operating costs, before interest and taxes. What it means here: the operating engine is efficient; the debt load is what compresses the bottom line. Everyday version: a contractor who earns $310 on every $1,000 job but owes so much on equipment loans that the bank takes most of it.
- $8.5 billion long-term debt, September 30, 2026 (Q3 2026 10-Q). What it is: the outstanding principal Organon owes to bondholders and lenders. What it means here: this figure is more than twice the company’s market value of $3.65 billion, so debt holders have a larger claim on the business than equity holders do. Everyday version: a family whose house is worth $365,000 but owes $850,000 on the mortgage. The bank owns the house; the family owns the hope.
- $14.00 per share, Sun Pharma acquisition price (announced April 2026). What it is: the all-cash price agreed for each Organon share. What it means here: with the stock at $13.90, the entire investment case for a new buyer is a ten-cent spread contingent on regulatory approval and deal close. That is an arbitrage position, not a fundamental one.
Sources
- Organon 10-Q, Q3 2026 (SEC EDGAR)
- Organon 10-Q, Q2 2026 (SEC EDGAR)
- Organon 10-Q, Q1 2026 (SEC EDGAR)
- Organon 10-K, FY2025 (SEC EDGAR)
- Organon 10-K, FY2023 (SEC EDGAR)
- Organon FY2025 earnings release
- Sun Pharma acquisition announcement, Dermatology Times
- Big Molecule Watch, Sun Pharma/Organon deal detail
- MarketBeat, OGN analyst consensus
- MarketBeat, OGN FDA events
- Forbes, Organon spin-off and debut earnings
- TradingView, Q3 2026 earnings summary
- NiftyTrader, Sun Pharma deal terms









